The development and execution of clinical trials that evaluate hemostatic products are impeded by the lack of commonly accepted outcomes by the necessary funding and regulatory agencies. The establishment of clinically relevant outcomes that are widely accepted for patients in clinical trials evaluating hemostatic blood products and therapeutics will enhance the ability to perform high quality clinical trials.
Canadian Blood Services recently updated the equipment it uses to produce components (red blood cells, plasma and platelets) from whole blood donations. In May 2019, the mammoth task of implementing the new equipment at manufacturing sites across the country was completed. But how did the organization choose which equipment to implement in the first place? Let’s look back at some early research work that helped the organization gather the evidence it needed to support this change.
The Centre for Innovation’s annual progress report details the achievements made over the past year by Canadian Blood Services’ network of scientists, medical experts, research partners, and collaborators.